empoweringmuscleempoweringlives
As a leader in muscle biology research, we are dedicated to our mission of improving the lives of people confronting devastating diseases of impaired muscle function.
Cytokinetics to Announce Third Quarter Results on October 26, 2017
SOUTH SAN FRANCISCO, Calif. , Oct. 12, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that it is scheduled to report third quarter results on October 26, 2017 at 4:00 PM Eastern Time . Following the announcement, Cytokinetics’ senior management will host a...
READ MORE ›als
People fighting amyotrophic lateral sclerosis have few treatment options; we are dedicated to changing the progression of this fatal disease.
Heart Failure
Heart failure death and disability rates continue to rise, despite current treatment options. With Amgen, we are developing a novel therapy that may improve cardiac performance in people with heart failure.
sma
People suffering from spinal muscular atrophy experience devastating loss of muscle function. With Astellas, we are working on a treatment that may enhance skeletal muscle performance in these and other patients.